TheraRadar
← Back
Data updated: Mar 29, 2026

SUPERNUS PHARMS

NeurologyDermatology
Specialty

SUPERNUS PHARMS is a specialty pharmaceutical company focused on Neurology, Dermatology. Key products include TROKENDI XR.

2012
Since
5
Drugs
-
Trials
5
Approved (2yr)

Key Drugs

TROKENDI XR
topiramate
CNS
AMPA/kainate receptor 5 indications · 2013
GOCOVRI
amantadine hydrochloride
CNS
NMDAR 2 indications · 2017
OXTELLAR XR
oxcarbazepine
High-voltage activated calcium channels 1 indications · 2012
QELBREE
viloxazine hydrochloride
Norepinephrine transporter 1 indications · 2021

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

GOCOVRI 2025-07-10
Labeling
OSMOLEX ER 2025-07-10
Labeling
TROKENDI XR 2025-03-10
Labeling
QELBREE 2025-01-23
Labeling
OXTELLAR XR 2024-08-14
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 75%
3 drugs
Dermatology 25%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Eli Lilly big-pharma
Neurology, Dermatology
LEDERLE big-pharma
Neurology, Dermatology
PAI HOLDINGS PHARM big-pharma
Dermatology, Neurology
ABBOTT big-pharma
Dermatology, Neurology
OTSUKA big-pharma
Neurology, Dermatology